Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) multiple-dose vials. It is used as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
The group also received the tentative approval for Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL), single-dose vial. It is used to mobilize hematopoietic stem cells into the bloodstream for their collection & subsequent transplantation in patients with certain type of blood cancers. It will be manufactured at Alidac Pharmaceuticals, a wholly owned subsidiary of Cadila Healthcare, located at the pharma SEZ in Ahmedabad.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group now has more than 190pprovals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.
